<DOC>
	<DOCNO>NCT01396954</DOCNO>
	<brief_summary>Glucose metabolism disorder ( GMD ) present overt subclinical way . They negative impact survival patient liver cirrhosis ( LC ) . Their prevalence determine compensate cirrhotic patient .</brief_summary>
	<brief_title>Cirrhosis-Diabetes</brief_title>
	<detailed_description>Overt Diabetes Mellitus ( DM ) observe 21 40 % patient liver cirrhosis ( LC ) . There two way DM relate LC : firstly , type 2 diabetes mellitus ( T2DM ) , genetic component often associate metabolic syndrome ( obesity , hypertriglyceridemia , hypertension ) , cause chronic liver disease ( steatosis , steatohepatitis , LC Secondly , LC may cause impaired glucose tolerance ( IGT ) DM . During initial stage LC metabolic disorder subclinical detect oral glucose tolerance test ( OGTT ) . As liver disease progress , DM become clinically evident . Diabetes mellitus secondary LC know `` hepatogenous diabetes '' ( HD ) . Although accepted LC diabetogenic condition , HD recognize American Diabetes Association WHO . Cirrhosis cause alcohol , HCV , hemochromatosis frequently associate HD etiology . It observe HCV core protein induce insulin resistance ( IR ) , steatosis , DM regardless body mass index ( BMI ) . Patients chronic alcoholism often chronic pancreatic damage result DM . In short , T2DM HD different etiology , seem similar pathophysiologic mechanism liver function deterioration . They increase risk complication death . In recent year , incidence obesity increase alarmingly world , particularly Western country . In Mexico , overweight obesity , suffer 70 % adult population serious public health problem , . This figure put country second place world , behind United States America . The incidence T2DM metabolic syndrome increase rapidly country . They become common cause cryptogenic cirrhosis Mexico . Many publish study , review prevalence DM cirrhotic patient , make distinction T2DM HD ; additionally , subclinical glucose metabolism disorder ( GMD ) routinely identify , magnitude problem underestimate . On hand , clinical biochemical feature cirrhotic patient different GMD know present . The clinical distinction GMD may useful prognosis therapeutic purpose . Based aforementioned , objectives present study : ) To establish prevalence clinical subclinical form GMD ( T2DM , HD , IGT ) cohort patient compensate LC diverse etiology ; b ) To determine clinical biochemical characteristic patient different GMD find whether significant difference among them..</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<criteria>presence biopsy clinically diagnose liver cirrhosis ; clinically compensate cirrhosis ; age 18 year ; sex Patients complication due liver disease ( hepatocellular carcinoma , alcoholic hepatitis , active gastrointestinal bleeding , hepatic encephalopathy , hepatorenal syndrome , severe infection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Liver cirrhosis</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Hepatogenous diabetes</keyword>
	<keyword>Oral glucose tolerance test</keyword>
	<keyword>Insulin resistance .</keyword>
</DOC>